Mediaroom - Sanofi

Skip to main content

FINANCIAL RESULTS

October 28, 2022

Third quarter 2022 results

Third quarter 2022 results will be reviewed by management during a conference call with the financial community. The presentation will be followed by a Q&A session.

SANOFI AT A GLANCE

Press releases

November 17, 2022

Press Release: European Commission approves Enjaymo® (sutimlimab) for treatment of hemolytic anemia in adult patients with cold agglutinin disease

November 11, 2022

Press Release: Dupixent® (dupilumab) recommended for EU approval by the CHMP for the treatment of prurigo nodularis

November 10, 2022

Press Release: Sanofi and GSK’s next-generation COVID-19 booster vaccine VidPrevtyn® Beta approved by the European Commission

November 4, 2022

Press Release: European Commission grants first approval worldwide of Beyfortus® (nirsevimab) for prevention of RSV disease in infants

October 28, 2022

Press Release: Continued strong growth in Q3 with key regulatory milestones achieved

ALL PRESS RELEASES

Contact the Media team

Global Media Relations Department
54 rue La Boétie
75008 Paris FRANCE
+33 (0)1 53 77 46 46 • mr@sanofi.com

ALL THE CONTACTS

You are a journalist and have a question about Sanofi, please contact the Global Media Relations team: please note the contact details are only for Medias. For any other request, please call the switchboard: +33 1 53 77 40 00

Email Alerts

SUBSCRIBE TO EMAIL ALERTS

Social feed

Resources

Sanofi at a glance

Publications

Our Integrated Report 2021

Annual Report on Form 20-F 2021

Half Year 2022 Financial Report

ALL THE PUBLICATIONS

Press Statements

Find out more about all our press statements

You are about to leave sanofi.com

If you wish to continue to this external website, click Proceed.

It is provided for information only. Sanofi assumes no responsibility for the information presented on this website.

PROCEED